MOUNTAIN VIEW, Calif. (AP) ¿ Vivus Inc. reported a smaller first-quarter loss on a dip in development costs for the obesity treatment candidate Qnexa.

The biopharmaceutical company said late Monday it lost $6.8 million, or 10 cents per share, in the three months ended March 31 compared with a loss of $7.1 million, or 12 cents per share, a year ago. Revenue slipped to $22.2 million from $22.7 million.

Analysts polled by Thomson Reuters expected a smaller loss of 7 cents per share on hgiher revenue of $23.7 million. The estimates typically exclude one-time items.

The revenue mainly came from the sale in 2007 of the spray-on hot flash treatment Evamist to K-V Pharmaceutical. Meanwhile, costs dipped on lower development expenses for Qnexa. The company is also developing vanafil as an erectile dysfunction treatment.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.